ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 755

Increased Degradation of BMPR2 in a TGFβ Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension

Adrian J Gilbane1, Emma C. Derrett-Smith2, Andrew Pearce3, Christopher P Denton4 and Alan M. Holmes5, 1Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 2Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, 3Respiratory Disease Area, Novartis, London, United Kingdom, 4Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom, 5Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lung Disease, Scleredema and mouse model

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose

Scleroderma patients are susceptible to development of pulmonary arterial hypertension (PAH) that has similarities to some forms of heritable PAH.  The basis for this susceptibility is unclear and SSc-PAH has a worse clinical outcome. We have previously shown that a TGFβ dependent mouse model of scleroderma (TβRIIΔk-fib) develops PAH in response to pulmonary endothelial cell injury. Using this model as a platform and clinical material form SSc lungs we explored expression and proteasomal degradation of BMPRII that is implicated in development of heritable PAH. 

Methods

We investigated BMP signalling in the lung in the TβRIIΔk-fib model of PAH-SSc in which TGFβ signalling is upregulated. The TβRIIΔk-fib mouse develops a structural pulmonary vasculopathy with smooth muscle hypertrophy and raised right ventricular pressures. Experiments were performed on whole lung isolates and explant cultured fibroblasts (n=6) from the TβRIIΔk-fib mouse and compared with wildtype controls. TGFβ/BMP signalling pathways were investigated by Western blot and immunohistochemistry and qPCR.  MG132, an inhibitor of proteasomal degradation, was used to explore the role of proteasomal degradation on BMPRII protein levels in vitro. 

Results

The TβRIIΔk-fib model has increased levels of pSmad2/3, indicative of enhanced TGFβ signalling. The TβRIIΔk-fib model exhibits a significant reduction in BMPRII protein expression in whole lung isolates (1.43, 0.38) (p<0.05), and explant cultured fibroblasts (0.299, 0.09) (p<0.05). A reduction of BMPRII was also observed in whole lung (0.095, 0.03) and explant cultured lung fibroblasts from SSc patients compared to healthy controls (p<0.05) but there was an increase in BMPRII gene expression. Interestingly, both TβRIIΔk-fib and SSc fibroblasts exhibited refractory responses to BMP4 (p<0.05). MG132 was able to restore BMPRII protein levels and restore BMP4 ligand response of SSc fibroblasts. 

Conclusion

Here we demonstrate the TβRIIΔk-fib transgenic murine model of PAH-SSc exhibits reduced expression of BMPRII as a reciprocal response to increased TGFβ signalling. Collectively our data suggests loss of BMPRII expression by non-genetic means may contribute to the development of PAH in SSc.  Further, our results suggest that use of a proteasomal degradation inhibitor might reduce the risk of developing PAH by restoring BMPRII expression.


Disclosure:

A. J. Gilbane,
None;

E. C. Derrett-Smith,
None;

A. Pearce,
None;

C. P. Denton,
None;

A. M. Holmes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-degradation-of-bmpr2-in-a-tgf%ce%b2-dependent-transgenic-mouse-model-of-scleroderma-with-susceptibility-to-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology